Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up

The British Journal of Ophthalmology
Morgane StraubCatherine Creuzot-Garcher

Abstract

To report a 10-year follow-up of patients suffering from severe dry eye syndrome (DES) initially treated with topical ciclosporin A (tCSA) for 6 months. The charts of 26 patients with severe DES related to keratoconjunctivitis sicca (KCS) and followed for a minimum 10-year follow-up were retrospectively reviewed. All of them were treated initially with tCSA for 6 months. The Schirmer I test, fluorescein and lissamine green staining scores and tear film break-up time (TBUT) were recorded to assess clinical symptoms before, during and after treatment. The subjective signs were evaluated with the ocular surface disease index (OSDI) questionnaire. Prolongation and reintroduction of tCSA after the initial treatment and combined treatments were also noted. Overall the median (IQR) duration of tCSA treatment was 23 (7-51) months after a prolonged induction treatment lasting 20 (8-41) months during the 10-year follow-up. For symptoms, a statistically significant difference in the OSDI between baseline and the end of the 10-year follow-up was not found (p=0.67). We noted a statistically significant improvement in all clinical signs after the initial treatment period, still present at the end of follow-up. Only 6.5% of the patients neede...Continue Reading

References

May 18, 2000·Archives of Ophthalmology·R M SchiffmanB L Reis
Feb 13, 2001·The British Journal of Ophthalmology·V A SmithD L Easty
May 15, 2002·Annals of the Rheumatic Diseases·C VitaliUNKNOWN European Study Group on Classification Criteria for Sjögren's Syndrome
Feb 14, 2004·American Journal of Ophthalmology·Stephen C Pflugfelder
Mar 10, 2004·Archives of Ophthalmology·Scot E MossBarbara E K Klein
Jul 3, 2004·Current Opinion in Ophthalmology·Henry D Perry, Eric D Donnenfeld
Jul 12, 2005·Current Medical Research and Opinion·Karl StonecipherDonna L Kerney
Sep 20, 2005·The British Journal of Ophthalmology·S Tatlipinar, E K Akpek
Mar 1, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Michael Rubin, Sanjay N Rao
Nov 15, 2006·Cornea·Ashley BehrensUNKNOWN Dysfunctional tear syndrome study group
Aug 19, 2008·Ophthalmology·Miki UchinoKazuo Tsubota
Nov 14, 2008·Expert Opinion on Pharmacotherapy·William H Ridder
Feb 16, 2010·European Journal of Ophthalmology·Bora YükselEngin Topaloğlu
Apr 27, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Sanjay N Rao
Aug 26, 2010·Ocular Immunology and Inflammation·Canan Asli UtineEsen K Akpek
Oct 18, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Sanjay N Rao
Dec 18, 2013·The British Journal of Ophthalmology·Marta SacchettiStefano Bonini

❮ Previous
Next ❯

Citations

Aug 25, 2019·Journal of Clinical Medicine·Yu-Kai KuoChing-Li Tseng
Nov 15, 2017·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·E M Messmer
Jan 7, 2021·Clinical & Experimental Ophthalmology·Shokufeh TavassoliElsie Chan

❮ Previous
Next ❯

Software Mentioned

Prism

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.